USV LTD
10 TABLETS IN A STRIP
ORAL DIABETIC DRUGS
Primarily Used For: Type II Diabetes mellitus
Alcohol Interaction: Alcohol interaction unknown
Food Interaction: Interaction with food is unknown, Consult a doctor for advice.
Common Side Effects:
Blurred vision, Respiratory tract infection, Bone fracture, Numbness.
.₹ 57.42
40% OFFPioglitazone is used in the treatment of type 2 diabetes.
Pioz 15mg Tablet 10's is used in
Pioglitazone is used in the treatment of type 2 diabetes.
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
Blurred vision, Respiratory tract infection, Bone fracture, Numbness.
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ARETAEUS PHARMACEUTICALS PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ARETAEUS PHARMACEUTICALS PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
STRIDES ARCOLAB LIMITED
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
STRIDES ARCOLAB LIMITED
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
STRIDES ARCOLAB LIMITED
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ARETAEUS PHARMACEUTICALS PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
LUPIN LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
LUPIN LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
LUPIN LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ERIS LIFE SCIENCES PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ERIS LIFE SCIENCES PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
USV LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
TORRENT PHARMACEUTICALS LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
MANKIND PHARMA PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
FULFORD INDIA LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ERIS LIFE SCIENCES PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
MICRO LABS LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
LUPIN LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
WALLACE PHARMACEUTICALS PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
WALLACE PHARMACEUTICALS PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
GLENMARK PHARMACEUTICALS LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
GLENMARK PHARMACEUTICALS LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
GLENMARK PHARMACEUTICALS LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
FDC LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ORGANON (INDIA) LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ORGANON (INDIA) LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
FDC LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
INTAS PHARMACEUTICALS LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
F D C LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
F D C LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
F D C LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
F D C LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ORDAIN HEALTH CARE GLOBAL PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
ORDAIN HEALTH CARE GLOBAL PVT LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
INTAS PHARMACEUTICALS LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
INTAS PHARMACEUTICALS LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
F D C LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
F D C LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
PARENTERAL DRUGS INDIA LTD
Pioglitazone reduces insulin resistance associated with type II diabetes mellitus without an increase in insulin secretion by pancreatic β cells. It decreases glucose production by liver and increases utilization of glucose by muscle and fat cells.
SANOFI INDIA LTD